Cancer pathology and molecular reports often contain terms such as MSI-High and dMMR.
Although these terms may sound complicated, they provide important information about how cancer cells repair damaged DNA.
Identifying these abnormalities can help doctors select appropriate treatment options, including certain immunotherapy medicines.
What Is Mismatch Repair?
Our cells have natural mechanisms to correct errors that occur when DNA is copied.
The mismatch repair system, also called MMR, helps identify and repair these errors.
Four important proteins involved in this system are:
- MLH1.
- MSH2.
- MSH6.
- PMS2.
When this repair system does not function properly, DNA errors can accumulate.
This condition is known as mismatch repair deficiency or dMMR.
What Is MSI-High?
Microsatellites are short, repeated DNA sequences found throughout the genome.
When the mismatch repair system is defective, errors can accumulate in these sequences.
This condition is called microsatellite instability.
MSI results may be classified as:
- MSI-High.
- MSI-Low.
- Microsatellite Stable (MSS).
MSI-High indicates a high level of instability in these DNA sequences.
What Is the Difference Between MSI-High and dMMR?
Both describe abnormalities related to DNA mismatch repair.
- dMMR: Indicates that the mismatch repair proteins are deficient or not functioning properly.
- MSI-High: Indicates instability in microsatellite DNA sequences.
They are closely related but are assessed using different laboratory methods.
Which Cancers May Show MSI-High or dMMR?
These findings are particularly relevant in:
- Colorectal cancer.
- Endometrial cancer.
- Gastric cancer.
- Small bowel cancer.
- Certain other solid tumours.
They are also important in evaluating the possibility of Lynch syndrome, an inherited cancer predisposition condition.
Why Is MSI/MMR Testing Important?
1. Treatment Planning
Some patients with MSI-High or dMMR advanced cancers may benefit from immune checkpoint inhibitors.
2. Prognostic Information
These findings may provide additional information about tumour characteristics, depending on the cancer type and stage.
3. Inherited Cancer Risk
Certain patterns of MMR protein loss may lead doctors to recommend additional genetic evaluation for Lynch syndrome.
Does MSI-High Mean Immunotherapy Is Always Required?
No.
MSI-High status may indicate eligibility for certain immunotherapy treatments in appropriate clinical settings. However, the decision depends on the cancer type, stage, previous treatment and approved indications.
Consult Dr. Ayush Dubey – Medical Oncologist in Raipur
MSI and MMR reports require careful interpretation alongside the patient’s diagnosis and medical history.
Dr. Ayush Dubey provides medical oncology consultation and guidance on biomarker-based cancer treatment.
Understanding the molecular characteristics of cancer can help doctors identify important treatment opportunities.